ClinicalTrials.gg
RecruitingNCT07704892NEBULA-2Updated Nov 5, 2026

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Phase 3 interventional study of Efimosfermin alfa and Placebo in Metabolic Dysfunction-associated Steatohepatitis, sponsored by GlaxoSmithKline. Recruiting at 35 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Primary conditionFatty LiverRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fatty Liver
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Fatty Liver.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 5, 202623 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 211 studies in Fatty Liver with a site in United States — 41 open to participants now, 47 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
11th of 162
380 · median 45
Started
2026
with 13 others
Phase 3
15 of 211
8 open now
Primary completion
2030-10
later than 43 of 46 live
Registered
205th of 211
by date
Lead sponsor
3 of 211
GlaxoSmithKline

Among the 211 studies in Fatty Liver with a site in United States, this one is the 11th largest by planned enrollment of the 162 interventional ones that give a count, is one of 14 that started in 2026, is one of 15 in phase 3, reaches primary completion later than 43 of the 46 other live ones, and was the 205th registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

41 of the 211 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusion criteria will have the option to enroll in Part B (open label) of the study.

03

Conditions studied

  • Metabolic Dysfunction-associated Steatohepatitis

Browse trials for

Keywords

  • Cirrhosis
  • Efimosfermin
  • Fibrosis
  • Metabolic dysfunction-associated
  • Steatohepatitis
04

In context

Fatty Liver Reclassified

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

This study's planned enrollment of 380 is above the median of 60 across 432 interventional studies indexed under Fatty Liver.

Browse Fatty Liver studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Fatty Liver, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged between 18 and 75 years at enrolment.
  • Participants with history or presence of at least two components of metabolic syndrome.
  • Liver consistent with cirrhosis (fibrosis stage 4).

Exclusion criteria

Exclusion Criteria:

  • Participants with other chronic liver diseases.
  • Participants with evidence or history of decompensated liver disease or hepatocellular carcinoma.
  • Participants with history of Type 1 diabetes mellitus; or major Type 2 diabetes mellitus complications.
  • History or evidence of chronic pancreatic disease; pancreatic injury or acute pancreatitis within 6 months before Screening.
  • A recent history or planned surgical procedures or medications intended to produce significant weight loss.
  • (ALT) or Aspartate aminotransferase (AST) >= 5 times upper limit normal ().
  • Current or history of excessive alcohol intake
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Part A: Participants receiving Efimosfermin alfa

    Participants will receive efimosfermin alfa in Part A of the study.

    Drug: Efimosfermin alfa

  • Placebo comparator
    Part A: Participants receiving Placebo

    Participants will receive placebo in Part A of the study.

    Drug: Placebo

  • Experimental
    Part B: Participants receiving Efimosfermin alfa

    All participants will receive efimosfermin alfa in Part B of the study.

    Drug: Efimosfermin alfa

Interventions

  • Efimosfermin alfa (subcutaneous injection) will be administered.

  • DrugPlacebo

    Placebo (subcutaneous injection) will be administered.

07

What researchers measure

Primary outcomes

  1. Part A: Proportion of participants achieving improvement in liver fibrosis by >=1 stage and no worsening of MASH

    Participants experiencing improvement in liver fibrosis of \>=1 stage (based on MASH Clinical Research Network (CRN) fibrosis score) and no worsening of MASH (defined as no increase in nonalcoholic fatty liver disease activity score for ballooning, inflammation, or steatosis). MASH CRN fibrosis score ranges from 0 to 4, higher score indicates greater severity.

    Time frame: At Week 96

Secondary outcomes

  1. Part A: Proportion of participants achieving change from Baseline in vibration-controlled transient elastography (VCTE)- liver stiffness measurement (LSM) and in enhanced liver fibrosis (ELF) score

    VCTE-LSM is a non-invasive test that uses vibration-controlled transient elastography to measure the stiffness of the liver in kilopascal (kPa). ELF score (scale of 6.7 to 11.3 with higher scores indicative of increased fibrosis) is a blood-based noninvasive test used as a prognostic marker for disease progression.

    Time frame: Baseline (Day 1) and Week 96

  2. Part A Change from Baseline in VCTE-LSM

    VCTE-LSM is a non-invasive test that uses vibration-controlled transient elastography to measure the stiffness of the liver in kPa.

    Time frame: Baseline (Day 1) and Week 96

  3. Part A: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) and TEAEs by severity

    Time frame: Week 96

  4. Part A: Proportion of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity

    Time frame: Week 96

  5. Part A: Proportion of participants with Grade 3 and Grade 4 laboratory abnormalities

    Time frame: Week 96

08

Study locations

35 of 35 sites recruiting
  • GSK Investigational Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • GSK Investigational Site
    Arcadia, California 91006, United States
    Recruiting
  • GSK Investigational Site
    Arroyo Grande, California 93420-3876, United States
    Recruiting
  • GSK Investigational Site
    Folsom, California 95630, United States
    Recruiting
  • GSK Investigational Site
    Van Nuys, California 91405, United States
    Recruiting
  • GSK Investigational Site
    Cape Coral, Florida 33914, United States
    Recruiting
  • GSK Investigational Site
    Fort Myers, Florida 33912, United States
    Recruiting
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
    Recruiting
  • GSK Investigational Site
    Homestead, Florida 33033, United States
    Recruiting
  • GSK Investigational Site
    Kissimmee, Florida 34744-4574, United States
    Recruiting
  • GSK Investigational Site
    Lakeland, Florida 33803, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33135-4661, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33155, United States
    Recruiting
  • GSK Investigational Site
    Ocala, Florida 34471, United States
    Recruiting
  • GSK Investigational Site
    University Park, Florida 34201, United States
    Recruiting
  • GSK Investigational Site
    St Louis, Missouri 63141, United States
    Recruiting
  • GSK Investigational Site
    East Syracuse, New York 13057, United States
    Recruiting
  • GSK Investigational Site
    New York, New York 10036-4103, United States
    Recruiting
  • GSK Investigational Site
    Morehead City, North Carolina 28557, United States
    Recruiting
  • GSK Investigational Site
    Springboro, Ohio 45066, United States
    Recruiting
  • GSK Investigational Site
    Westlake, Ohio 44145-1493, United States
    Recruiting
  • GSK Investigational Site
    Arlington, Texas 76012, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78745-5675, United States
    Recruiting
  • GSK Investigational Site
    Austin, Texas 78759, United States
    Recruiting
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
    Recruiting
  • GSK Investigational Site
    Dallas, Texas 75243-1921, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77058-2805, United States
    Recruiting
  • GSK Investigational Site
    Humble, Texas 77346, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78209, United States
    Recruiting
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
    Recruiting
  • GSK Investigational Site
    Waco, Texas 76710, United States
    Recruiting
  • GSK Investigational Site
    West Jordan, Utah 84088, United States
    Recruiting
  • GSK Investigational Site
    Manassas, Virginia 20110, United States
    Recruiting
  • GSK Investigational Site
    Ōgaki, Gifu 503-8502, Japan
    Recruiting
  • GSK Investigational Site
    Kawasaki-shi, 215-0026, Japan
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Oct 2030, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartActual
Jul 22, 2026
Primary completionEst.
Oct 16, 2030
CompletionEst.
Dec 8, 2033
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
23 sites added
Show 23 added (23 United States)
  • GSK Investigational Site · Folsom, United States
  • GSK Investigational Site · St Louis, United States
  • GSK Investigational Site · New York, United States
  • GSK Investigational Site · Morehead City, United States
  • GSK Investigational Site · Arlington, United States
  • GSK Investigational Site · Bellaire, United States
  • GSK Investigational Site · Houston, United States
  • GSK Investigational Site · San Antonio, United States
  • GSK Investigational Site · Arcadia, United States
  • GSK Investigational Site · Arroyo Grande, United States
  • GSK Investigational Site · Van Nuys, United States
  • GSK Investigational Site · Cape Coral, United States
  • GSK Investigational Site · Fort Myers, United States
  • GSK Investigational Site · Hialeah, United States
  • GSK Investigational Site · Homestead, United States
  • GSK Investigational Site · Kissimmee, United States
  • GSK Investigational Site · Lakeland, United States
  • GSK Investigational Site · University Park, United States
  • GSK Investigational Site · East Syracuse, United States
  • GSK Investigational Site · Austin, United States
  • GSK Investigational Site · Waco, United States
  • GSK Investigational Site · West Jordan, United States
  • GSK Investigational Site · Manassas, United States
across 2 updates, Sep 30, 2026 – Nov 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • GSK Investigational Site · San Antonio, United StatesContact person changed (no phone or email listed)
Sep 30, 2026
Show all 2 updates
  1. Nov 5, 2026
    15 sites added
    Show 15 added (15 United States)
    • GSK Investigational Site · Arcadia, United States
    • GSK Investigational Site · Arroyo Grande, United States
    • GSK Investigational Site · Van Nuys, United States
    • GSK Investigational Site · Cape Coral, United States
    • GSK Investigational Site · Fort Myers, United States
    • GSK Investigational Site · Hialeah, United States
    • GSK Investigational Site · Homestead, United States
    • GSK Investigational Site · Kissimmee, United States
    • GSK Investigational Site · Lakeland, United States
    • GSK Investigational Site · University Park, United States
    • GSK Investigational Site · East Syracuse, United States
    • GSK Investigational Site · Austin, United States
    • GSK Investigational Site · Waco, United States
    • GSK Investigational Site · West Jordan, United States
    • GSK Investigational Site · Manassas, United States
    + 2 other changes: identifiers and verification date
  2. Sep 30, 2026
    8 sites added
    Show 8 added (8 United States)
    • GSK Investigational Site · Folsom, United States
    • GSK Investigational Site · St Louis, United States
    • GSK Investigational Site · New York, United States
    • GSK Investigational Site · Morehead City, United States
    • GSK Investigational Site · Arlington, United States
    • GSK Investigational Site · Bellaire, United States
    • GSK Investigational Site · Houston, United States
    • GSK Investigational Site · San Antonio, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • GSK Investigational Site · San Antonio, United StatesContact person changed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07704892
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Jul 22, 2026
Primary completion
Oct 16, 2030 (estimated)
Completion
Dec 8, 2033 (estimated)
Last update
Nov 5, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efimosfermin alfa

Start the discussion